TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03821402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DAXI for injection 250 U
Description: DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DAXI for injection 375 U
Description: DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DAXI for injection 500 U
Description: DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
Study: NCT06016049

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMLA® adjuvant
Description: cutaneous forearm deafferentation
Study: NCT01817556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mucosta Tab.
Study: NCT03146091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nonantibiotic treatment of uncomplicated diverticulitis
Description: Patients randomized to this arm will be treated without antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic treatment of uncomplicated diverticulitis
Description: Patients randomized to this arm will be treated with antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
Study: NCT02750761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid Phosphate (IV)
Description: 200 mg/vial powder for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid Phosphate (IV)
Description: 200 mg/vial powder for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid Phosphate (IV)
Description: 200 mg/vial powder for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid Phosphate (IV)
Description: 200 mg/vial powder for injection
Study: NCT06016049

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sensory training
Description: Sensibility training of the median nerve

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sensory training
Description: Sensibility training of the median nerve
Study: NCT02750761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid Phosphate (oral suspension)
Description: Powder for oral suspension 20 mg/mL following reconstitution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid Phosphate (oral suspension)
Description: Powder for oral suspension 20 mg/mL following reconstitution
Study: NCT00424489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplantation
Description: Autologous Hematopoietic Stem Cell Transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG (rabbit)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Study: NCT03882047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Mometasone furoate nasal spray, 200 mg once daily
Study: NCT01777386

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preexpanded perforator flap surgery
Study: NCT04937218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Egg demand creation campaign
Description: Egg demand creation campaign including 14 months of above-the-line and below-the-line messaging.
Study: NCT04086901

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy dose escalation
Description: Flour-Deoxy-Glucose /Positron Emissions Tomografi (FDG-PET) scans will be used to identify and delineate the tumour sub-volumes with the highest tracer uptake to guide the dose-escalation. The dose to the Gross tumor volume (GTV) will be escalated to a high dose while clinical target volume (CTV) and planning target volume (PTV) will be treated with standard dose.
Study: NCT03882047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fluticasone propionate nasal spray, 200 mg once daily
Study: NCT03529032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: methadone for control postoperative pain
Study: NCT03882047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate placebo
Description: Mometasone furoate placebo matching nasal spray, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate placebo
Description: Mometasone furoate placebo matching nasal spray, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate placebo
Description: Fluticasone propionate placebo matching nasal spray, once daily
Study: NCT03461614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Exercise group mainly conducted the 5 core stabilization exercises as described by McGill. These include the curl-up, side bridge, trunk extension, double leg lifts and bird-dog exercises that support respiratory functions. In other words, every single training session consisted of frontal, dorsal, and lateral core exercise. In general, participants always exercised in group so that for integration and motivation. During training weeks 1-2, participants exercises with 3 sets per exercise and 10 s contraction time and 10 repetitions. During training weeks 3-4, contraction times and repetitions were increased to 15 s and 15 repetitions. Additionally, increasing the complexity of exercises, adding opposite limb movements and increasing the lever arm of the exercises were done.
Study: NCT03882047

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone propionate placebo
Description: Fluticasone propionate placebo matching nasal spray, once daily
Study: NCT00952783

Intervention type: DRUG
Intervention: Lesion count
Description: Lesion count in area treated by study drug in a prior study over a 12 month period No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
Study: NCT04414215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional working memory training
Description: Participants will complete an emotional working memory n-back training program that progressively increases difficulty and has been shown to enhance prefrontal activity in a non-psychiatric sample

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo working memory training
Description: Working memory training that does not involve emotional stimuli using an N-back training program
Study: NCT02456532

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: six months of nightly placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem CR
Description: six months of nightly zolpidem

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone
Study: NCT04314739

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Participants will consume one of the treatment types daily for a period of four weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume one of the treatment types daily for a period of four weeks.
Study: NCT03882320

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient Controlled Analgesia (PCA)
Description: Patient Controlled Analgesia (PCA)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient Controlled Analgesia (PCA)
Description: Patient Controlled Analgesia (PCA)
Study: NCT00376220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Initially dispensed 50 mg capsules to take twice a day (BID). At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules in the morning (qAM), two capsules in the evening (qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as Montgomery Asberg Depression Rating Scale (MADRS) \< 12) the dose will not be increased further unless clinical symptoms recur.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Initially dispensed 50mg capsules to take BID. At two weeks increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules qAM, two capsules qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as MADRS \< 12) the dose will not be increased further unless clinical symptoms recur.
Study: NCT03713268

Intervention type: DEVICE
Intervention: Microscope integrated optical coherence tomography
Description: This is translational study in which subjects will either be imaged with a microscope integrated optical coherence tomography (MIOCT) system or they will use MIOCT during surgical procedures. OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, cornea, optic nerve head and retinal blood vessels. The MIOCT has been integrated into the surgical microscope used in retinal and anterior segment surgeries so it does not touch the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the patient is not disturbed by the light.

Intervention type: DEVICE
Intervention: Microscope integrated optical coherence tomography
Description: This is translational study in which subjects will either be imaged with a microscope integrated optical coherence tomography (MIOCT) system or they will use MIOCT during surgical procedures. OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, cornea, optic nerve head and retinal blood vessels. The MIOCT has been integrated into the surgical microscope used in retinal and anterior segment surgeries so it does not touch the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the patient is not disturbed by the light.

Intervention type: DEVICE
Intervention: Microscope integrated optical coherence tomography
Description: This is translational study in which subjects will either be imaged with a microscope integrated optical coherence tomography (MIOCT) system or they will use MIOCT during surgical procedures. OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, cornea, optic nerve head and retinal blood vessels. The MIOCT has been integrated into the surgical microscope used in retinal and anterior segment surgeries so it does not touch the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the patient is not disturbed by the light.
Study: NCT04068142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Supporter Safety Planning
Description: The rationale for testing a peer-delivered intervention in the ED relies on the following evidence: a) a peer is an individual with lived experience who is now supporting other mental health patients in crisis; b) the experience of a mental health patient in the ED often shapes the perception of the health system, and may influence willingness to seek future care; c) peers may provide more empathetic care than providers without lived experience, which may positively impact patients; d) peer-based programs for patients with serious mental illness that do not involve safety planning are at least as good as non-peer based programs at preventing hospitalizations and promoting engagement in care, with the most promising interventions involving self-management or peer-navigator roles; and e) existing evidence from high-quality studies is scarce, but in moderate-low quality studies has indicated that peers are no less effective than mental health workers
Study: NCT02563522

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Engensis (VM202)
Description: gene therapy
Study: NCT03461614

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: In addition to the service routine rehabilitation program mentioned above, participants in the Control group participated in leisure activities such as table tennis/basketball under service staff supervision for 45-60 minutes, 2 times a week, 6 weeks similar time period of Exercise group.
Study: NCT02426021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1202
Description: Subcutaneous administration of MLN1202
Study: NCT02563522

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard of care plus placebo
Study: NCT03365323

Intervention type: OTHER
Intervention: Periprosthetic Joint Infection
Description: Periprosthetic Joint Infection is diagnosed according to the diagnosing criteria from the Workgroup of the Musculoskeletal Infection Society.

Intervention type: OTHER
Intervention: Non-Periprosthetic Joint Infection
Description: PJI can not be diagnosed for the lack of clinical evidence according to the diagnosing criteria from the Workgroup of the Musculoskeletal Infection Society.
Study: NCT02426021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1202
Description: Subcutaneous administration of MLN1202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1202
Description: Subcutaneous administration of MLN1202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1202
Description: Subcutaneous administration of MLN1202
Study: NCT00681720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: Single dose of oral solution or capsule. 3 times per subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radioligand (11C) flumazenil
Description: Single dose of i.v solution. 4 times per subject. (3 times together with AZD7325)
Study: NCT02745977

Intervention type: OTHER
Group type: OTHER
Intervention: Dairy Free Diet
Description: Dairy Free Diet x 3 stool guaiacs. If positive, dairy is reintroduced to diet.
Study: NCT02426021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1202
Description: Subcutaneous administration of MLN1202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1202
Description: Subcutaneous administration of MLN1202
Study: NCT00668070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP9831
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP9831
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT01429584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interscalene nerve block with 0.25% bupivacaine
Description: interscalene nerve block performed with 20 ml of 0.25% bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interscalene block with 0.125% bupivacaine
Description: interscalene block with 20 ml of 0.125% bupivacaine
Study: NCT00747643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: Participants in this group received varenicline according to the schedule in the Arm Description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants in this group received a placebo and did not receive any active medication according to the schedule in the Arm Description.
Study: NCT03588351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chitosan nanoparticles gel
Description: intracanal medicament

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chitosan gel
Description: intracanal medicament

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine gluconate
Description: intracanal medicament
Study: NCT03215550

Intervention type: PROCEDURE
Intervention: CEA
Description: Carotid Endarterectomy

Intervention type: RADIATION
Intervention: 18F PET-MRI
Description: 18F-fluoride Hybrid PET-MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Doppler
Description: Microembolic Signals detection
Study: NCT02847455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg ilaprazole
Description: One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg ilaprazole
Description: Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Rabeprazole
Description: one 10-mg Rabeprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
Study: NCT00737256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: 15-30 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perphenazine
Description: 8-16 mg
Study: NCT01357096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated health care team
Description: CAD education fryers, drugs counseling, diet intervention, individualized exercise program, body weight control, smoking cessation program, and distant CAD care monitoring

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Traditional group
Description: CAD education fryers
Study: NCT00063141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Vial, IV, 400 mg/m² week 1 then 250 mg/m², weekly, until PD/Toxicity/Pt-PI Decision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
Study: NCT01187966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03897907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychologically Informed Education Video
Description: The education session will teach participants how the body processes nociception and experiences pain, and pain does not mean tissues are being damaged. Additionally we will use the framework called the Common Sense Model of Self-Regulation which advocates for education to address five cognitive dimensions: (1) identity (the effort to evaluate symptoms and label the illness); (2) cause (the subjectively formulated belief of what is causing the symptoms); (3) time-line (the patient's perception of how long the problem will last); (4) consequences (the patient's predictions of how the illness will affect them in different areas of their life); and (5) controllability (the patient's belief regarding their outcome and personal ability to change it)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anatomy Education Video
Description: Participants in the control group will watch three videos equal in length to the psychologically-informed videos. The control videos will discuss anatomy of the lower extremity, basic instruction in proper lower extremity biomechanics, and simple lower extremity exercises. The control videos will provide no psychologically-informed education or positive reinforcement about the condition.
Study: NCT00641550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Walking 3 times a week during 1 hours (moderate activity)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Walking 3 times a week during 1 hours (moderate activity)
Study: NCT04155255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyBFF@school
Study: NCT00319150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erythropoietin
Description: Decrease dosage by 12.5% q 2 weeks according to an algorithm.
Study: NCT03722342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTAC-0001 and pembrolizumab combination
Description: * Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)~* Treatment groups: 3 dose levels~  * Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~* Cycle: 3 weeks (21 days per cycle)
Study: NCT04501068

Intervention type: DEVICE
Intervention: Ambu® AuraGainTM
Description: Evaluate the time of insertion, performance, security and insertion success rate of the Ambu® AuraGainTM in patients undergoing ambulatory surgery and general anaesthesia
Study: NCT03416270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 12 weeks